← All trials
NCT06941142
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2025
- Primary completion
- Oct 31, 2027
- Completion date
- Jun 30, 2028
- First posted
- Apr 23, 2025
- Last posted
- Apr 23, 2025
- Enrollment
- 382
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shijiazhuang Pharma Group (CSPC)Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.